Search
Search Results
-
The histone deacetylase SIRT6 promotes glycolysis through the HIF-1α/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer
Erlotinib is a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Overcoming erlotinib resistance is crucial to...
-
Antitumor effects of erlotinib in combination with berberine in A431 cells
BackgroundFirst-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as erlotinib, have been shown to target...
-
Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib
BackgroundPancreatic adenocarcinoma (PC) is an aggressive malignancy with limited treatment options. The poor prognosis primarily stems from...
-
M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way
BackgroundThe small tyrosine kinase inhibitors (TKIs) subversively altered the lung cancer treatments, but patients will inevitably face the therapy...
-
-
Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
BackgroundAlthough kinase inhibitors (KIs) are generally effective, their use has a large impact on the current health care budget. Dosing strategies...
-
Cancer Drug Resistance and Metabolic Reprogramming
There is a complex and strong association between metabolic reprogramming and the phenomenon of drug resistance in cancer. Cancer cell metabolic...
-
Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase
Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant forms of cancer. Lack of effective treatment options and drug resistance...
-
Promoting reactive oxygen species accumulation to overcome tyrosine kinase inhibitor resistance in cancer
BackgroundIn tumor treatment, protein tyrosine kinase inhibitors (TKIs) have been extensively utilized. However, the efficacy of TKI is significantly...
-
Resistance to Targeted Therapy in Breast Cancer
The discoveries of breast cancer molecular subtypes and their deregulated pathways have given rise to the emergence of potential therapeutic targets...
-
Role of Cancer Stem Cells in Drug Resistance
The chapter on the “Role of Cancer Stem Cells in Drug Resistance” explores the intricate mechanisms underlying the resistance of cancer stem cells...
-
Future Directions and Challenges in Overcoming Drug Resistance in Cancer
The chapter Future Directions and Challenges in Overcoming Drug Resistance in Cancer explores crucial aspects, primarily focusing on two key topics:...
-
AXL in cancer: a modulator of drug resistance and therapeutic target
AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to...
-
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor...
-
Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
Erythropoietin-producing hepatocellular A2 (EphA2) is a vital member of the Eph tyrosine kinase receptor family and has been associated with...
-
Partial response to erlotinib in a patient with imatinib-refractory sacral chordoma
BackgroundChordoma is a rare, slow growing and locally aggressive mesenchymal neoplasm with uncommon distant metastases. It is a chemo-resistant...
-
The role of m6A methylation in therapy resistance in cancer
Cancer therapy resistance is the main cause of cancer treatment failure. The mechanism of therapy resistance is a hot topic in epigenetics. As one of...
-
Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance
Chemotherapy, radiotherapy, targeted therapy, and immunotherapy are established cancer treatment modalities that are widely used due to their...
-
Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance
Cancer is a complex disease displaying a variety of cell states and phenotypes. This diversity, known as cancer cell plasticity, confers cancer cells...
-
Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma
BackgroundElafin is a serine protease inhibitor critical for host defence. We previously reported that Elafin was associated with the recurrence of...
